TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tango Therapeutics Inc (TNGX) is not a strong buy at this moment for a beginner investor with a long-term horizon. While the stock has bullish technical indicators and positive analyst ratings, the lack of recent news, insider selling, poor financial performance, and negative short-term stock trend forecasts suggest caution. Holding off for now and monitoring for better entry points or catalysts is recommended.
The technical indicators are moderately bullish. The MACD histogram is above 0 and positively contracting, suggesting upward momentum. RSI is neutral at 59.793, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance is at 27.683, with support at 21.017. However, the stock's short-term trend indicates a potential decline (-0.97% next day, -5.84% next week, -5.44% next month).
Analysts have a strong consensus of Buy ratings with multiple price target increases, including a recent initiation by Canaccord with a $30 target. Tango's lead program, vopimetostat, shows promise in precision oncology with potential 'best-in-class' opportunities. Upcoming data readouts in 2026 are expected to be significant catalysts.
Insiders are selling heavily, with a 181.42% increase in selling activity over the last month. Financial performance is weak, with revenue dropping to zero in Q4 2025 and EPS declining 14.71% YoY. No recent news or congress trading data is available to support a bullish sentiment. Short-term stock trend analysis indicates potential declines.
The company's Q4 2025 financials show significant weaknesses. Revenue dropped to $0 (-100% YoY), EPS decreased to -0.29 (-14.71% YoY), and net income remains negative at -$38.75M, though it improved slightly by 2.86% YoY. Gross margin remains at 100%, but this is not meaningful given the lack of revenue.
Analysts are bullish on TNGX, with multiple Buy ratings and price target increases. Recent targets range from $19 to $30, with optimism around vopimetostat's potential in oncology. However, the key catalysts are expected in 2026, which may not align with the user's impatience for immediate returns.
